BioInfra바이오인프라

BioInfra's shares have roughly tripled in a month, but the company is loss-making and faces delisting-related filings and notices.

BioInfra, a Korean contract research organization, reported a net loss of about ₩8.3B over the trailing twelve months to H1 2026 after a ₩9.1B loss in 2025, while revenue and operating figures are not in the data. Its share price closed at ₩2,575 on 2026-10-16, up 201.9% over one month but down 47% over one year, and recent filings include a merger decision and several delisting-related notices.

What stands out

• Net income was negative in 2025 (about -₩9.1B) and in the trailing twelve months to H1 2026 (about -₩8.3B), with return on equity at -41.3%.
• Revenue, operating income and margins are missing from the data for recent periods, so the scale of the current business cannot be measured from it.
• The last year with full reported revenue was 2023 at about ₩30.1B, down 15% from 2022, with an operating margin of 4.3%.
• Liabilities are 171.4% of equity, and trailing free cash flow was about -₩2.5B against cash of about ₩2.8B.
• Filings include a merger decision (September 2026), delisting notices and a notice about potential administrative designation over market capitalisation below ₩20B, while news reports describe a 'delisting deferral' rally.

What to watch

• Whether the merger and delisting-related filings lead to a formal delisting decision or a deferral, as news reports suggest is being discussed.
• The next half-year or annual filings, which should show whether revenue and operating income are reported again.
• Share price volatility: recent gains are large, while the stock is still down over one year and the data does not show the drivers.